Bluechiip Ltd Investor Presentation
Melbourne, April 27, 2017 - (ABN Newswire) - Bluechiip Ltd (ASX:BCT) is pleased to provide the Company's latest Investor Presentation.
Bluechiip Highlights
- Highly differentiated, expanding, protected core technology
- Chasing immediate, addressable market of US$250 million + from 3 recently executed licence and supply agreements
o Genea Biomedx - IVF Market (US$20M) with upcoming product launch through Merck o Planet Innovation - Cryopreservation, transport and life sciences (US$30M) market opportunities o Labcon North America - Biopreservation market (US$200M) with initial 2ml vial market ($40M)
- Growing target bio-preservation market (>US$2B) & very large adjacent markets
- Dramatically increasing partner pipeline with well advanced product development
- Growing initial repeat licence, service and product revenues
- Expected significant revenue growth in FY'18 on partner's product launch
To view the full presentation, please visit: http://abnnewswire.net/lnk/2Y01PE9J
About: Bluechiip Ltd
Founded in 2003 and ASX listed in 2011, Bluechiip Ltd (ASX:BCT) has its head office in Melbourne, Australia and distribution channels around the globe.
Bluechiip's unique and patented technology combines secure wireless sample tracking with integrated temperature reading for use in extreme environments, working reliably in temperatures from -196DEG C to +200DEG C, and impervious to autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Based on MEMS technology, the Bluechiip(R) tag contains no electronics. Unlike traditional tracking technology like labels, barcodes or RFID, Bluechiip does not require line-of-sight visibility for temperature readings and tracking, and so can be read through frost without damaging the sample.
The tag can either be embedded or manufactured into storage products such as vials or bags. Easy identification, along with any associated information from the tag can be detected by a reader, which can also sense the temperature of the tagged items. Unlike other tracking methods, the Bluechiip(R) technology can sense the temperature of each item a tag is attached to or embedded in.
This technology is particularly important for industries such as the $2b biopreservation and cryopreservation market, which processes more than 300 million samples per year of tissue, blood, serum, plasma, etc., for industries such as pharmaceuticals, IVF, research and clinical trials. It also has applications in cold chain logistics, food, manufacturing, security and defence.
Further information is available at http://www.bluechiip.com
Bluechiip Highlights
- Highly differentiated, expanding, protected core technology
- Chasing immediate, addressable market of US$250 million + from 3 recently executed licence and supply agreements
o Genea Biomedx - IVF Market (US$20M) with upcoming product launch through Merck o Planet Innovation - Cryopreservation, transport and life sciences (US$30M) market opportunities o Labcon North America - Biopreservation market (US$200M) with initial 2ml vial market ($40M)
- Growing target bio-preservation market (>US$2B) & very large adjacent markets
- Dramatically increasing partner pipeline with well advanced product development
- Growing initial repeat licence, service and product revenues
- Expected significant revenue growth in FY'18 on partner's product launch
To view the full presentation, please visit: http://abnnewswire.net/lnk/2Y01PE9J
About: Bluechiip Ltd
Founded in 2003 and ASX listed in 2011, Bluechiip Ltd (ASX:BCT) has its head office in Melbourne, Australia and distribution channels around the globe.
Bluechiip's unique and patented technology combines secure wireless sample tracking with integrated temperature reading for use in extreme environments, working reliably in temperatures from -196DEG C to +200DEG C, and impervious to autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Based on MEMS technology, the Bluechiip(R) tag contains no electronics. Unlike traditional tracking technology like labels, barcodes or RFID, Bluechiip does not require line-of-sight visibility for temperature readings and tracking, and so can be read through frost without damaging the sample.
The tag can either be embedded or manufactured into storage products such as vials or bags. Easy identification, along with any associated information from the tag can be detected by a reader, which can also sense the temperature of the tagged items. Unlike other tracking methods, the Bluechiip(R) technology can sense the temperature of each item a tag is attached to or embedded in.
This technology is particularly important for industries such as the $2b biopreservation and cryopreservation market, which processes more than 300 million samples per year of tissue, blood, serum, plasma, etc., for industries such as pharmaceuticals, IVF, research and clinical trials. It also has applications in cold chain logistics, food, manufacturing, security and defence.
Further information is available at http://www.bluechiip.com